BRPI0913212A2 - composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato - Google Patents
composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvatoInfo
- Publication number
- BRPI0913212A2 BRPI0913212A2 BRPI0913212A BRPI0913212A BRPI0913212A2 BR PI0913212 A2 BRPI0913212 A2 BR PI0913212A2 BR PI0913212 A BRPI0913212 A BR PI0913212A BR PI0913212 A BRPI0913212 A BR PI0913212A BR PI0913212 A2 BRPI0913212 A2 BR PI0913212A2
- Authority
- BR
- Brazil
- Prior art keywords
- carbinol
- solvate
- drug
- salt
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5707008P | 2008-05-29 | 2008-05-29 | |
PCT/JP2009/002406 WO2009144961A1 (ja) | 2008-05-29 | 2009-05-29 | 環状リンカーを有する置換カルビノール化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0913212A2 true BRPI0913212A2 (pt) | 2019-09-24 |
Family
ID=41376850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0913212A BRPI0913212A2 (pt) | 2008-05-29 | 2009-05-29 | composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato |
Country Status (15)
Country | Link |
---|---|
US (1) | US8153634B2 (pt) |
EP (1) | EP2281817A4 (pt) |
JP (1) | JP5541803B2 (pt) |
KR (1) | KR20110025899A (pt) |
CN (1) | CN102105452A (pt) |
AU (1) | AU2009252615B2 (pt) |
BR (1) | BRPI0913212A2 (pt) |
CA (1) | CA2725111A1 (pt) |
EA (1) | EA018584B1 (pt) |
IL (1) | IL209489A0 (pt) |
MX (1) | MX2010012882A (pt) |
NZ (1) | NZ589504A (pt) |
TW (1) | TW201010983A (pt) |
WO (1) | WO2009144961A1 (pt) |
ZA (1) | ZA201008424B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011011281A (es) * | 2009-04-29 | 2012-02-22 | Kowa Co | Compuesto de carbinol que tiene un enlazante heterociclico. |
US20120258891A1 (en) | 2011-04-07 | 2012-10-11 | Nimblegen Systems Gmbh | Diarylsulfide backbone containing photolabile protecting groups |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
CN104387317B (zh) * | 2014-11-27 | 2017-05-10 | 安徽星宇化工有限公司 | 一种6‑氯烟酸的制备方法及分离纯化方法 |
CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
WO2018068295A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
CN108276392A (zh) * | 2017-01-05 | 2018-07-13 | 浙江东方基因生物制品股份有限公司 | 亚甲基二氧吡咯戊酮人工抗原的制备方法以及运用 |
CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
MX2020009228A (es) | 2018-03-08 | 2021-01-08 | Incyte Corp | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
EP3936192A4 (en) | 2019-03-06 | 2022-11-16 | Daiichi Sankyo Company, Limited | PYRROLOPYRAZOL DERIVATIVES |
CZ309045B6 (cs) * | 2019-04-08 | 2021-12-22 | Univerzita Palackého v Olomouci | Způsob přípravy 6-amino-2,3-difluorbenzonitrilu |
JP2023509845A (ja) | 2019-12-13 | 2023-03-10 | インスピルナ,インコーポレーテッド | 金属塩及びその使用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE335993C (de) | 1916-02-02 | 1921-04-20 | Chem Fab Von Heyden Aktien Ges | Verfahren zur Herstellung von Hydantoinen |
US3396159A (en) | 1965-06-15 | 1968-08-06 | Squibb & Sons Inc | Penicillin and cephalosporin derivatives |
DE3713872A1 (de) | 1987-04-25 | 1988-11-17 | Hoechst Ag | Substituierte chinoxalyl-imidazolidin-2,4-dione, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel sowie pharmazeutische praeparate |
ATE147400T1 (de) * | 1991-08-13 | 1997-01-15 | Bayer Ag | Fluoreszierendes etikett |
US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
DE60107449T2 (de) | 2000-09-18 | 2005-12-08 | Glaxo Group Ltd., Greenford | Substituierte aminopropoxyarylderivate als lxr agonisten |
ATE453389T1 (de) | 2002-03-27 | 2010-01-15 | Smithkline Beecham Corp | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen |
EP1407774A1 (en) | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
WO2004072046A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
WO2005023188A2 (en) | 2003-09-03 | 2005-03-17 | Smithkline Beecham Corporation | Compounds and methods |
JP2006193426A (ja) * | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−4(3h)−オン化合物 |
PA8619901A1 (es) | 2003-12-12 | 2005-11-25 | Wyeth Corp | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares |
BRPI0509275A (pt) * | 2004-03-26 | 2007-09-04 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas de lxr(alfa) e/ou lxr(beta) e utilização dos mesmos |
NL1026431C1 (nl) | 2004-06-16 | 2005-12-19 | Umc Utrecht Holding Bv | Inrichting voor het opwekken van elektrische stroomvelden in een menselijk lichaam en werkwijze voor het gebruik daarvan. |
JP4620123B2 (ja) | 2004-10-01 | 2011-01-26 | エフ.ホフマン−ラ ロシュ アーゲー | ヘキサフルオロイソプロパノール置換エーテル誘導体 |
JP2007284367A (ja) | 2006-04-14 | 2007-11-01 | Kowa Co | Lxrアゴニスト |
EP2098515B1 (en) | 2006-11-30 | 2012-02-08 | Kowa Company, Ltd. | Substituted carbinol compound |
US8008306B2 (en) * | 2008-04-30 | 2011-08-30 | Kowa Company, Ltd. | Quinoline compounds |
JP2009286788A (ja) * | 2008-05-29 | 2009-12-10 | Kowa Co | 新規な置換カルビノール化合物 |
-
2009
- 2009-05-29 JP JP2010514385A patent/JP5541803B2/ja not_active Expired - Fee Related
- 2009-05-29 KR KR1020107026304A patent/KR20110025899A/ko not_active Application Discontinuation
- 2009-05-29 BR BRPI0913212A patent/BRPI0913212A2/pt not_active IP Right Cessation
- 2009-05-29 NZ NZ589504A patent/NZ589504A/xx not_active IP Right Cessation
- 2009-05-29 AU AU2009252615A patent/AU2009252615B2/en not_active Expired - Fee Related
- 2009-05-29 US US12/474,799 patent/US8153634B2/en not_active Expired - Fee Related
- 2009-05-29 WO PCT/JP2009/002406 patent/WO2009144961A1/ja active Application Filing
- 2009-05-29 CA CA2725111A patent/CA2725111A1/en not_active Abandoned
- 2009-05-29 MX MX2010012882A patent/MX2010012882A/es active IP Right Grant
- 2009-05-29 EA EA201071238A patent/EA018584B1/ru not_active IP Right Cessation
- 2009-05-29 EP EP09754469A patent/EP2281817A4/en not_active Withdrawn
- 2009-05-29 CN CN2009801288988A patent/CN102105452A/zh active Pending
- 2009-06-01 TW TW098118098A patent/TW201010983A/zh unknown
-
2010
- 2010-11-21 IL IL209489A patent/IL209489A0/en unknown
- 2010-11-24 ZA ZA2010/08424A patent/ZA201008424B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201071238A1 (ru) | 2011-06-30 |
CN102105452A (zh) | 2011-06-22 |
CA2725111A1 (en) | 2009-12-03 |
NZ589504A (en) | 2012-07-27 |
JPWO2009144961A1 (ja) | 2011-10-06 |
AU2009252615A1 (en) | 2009-12-03 |
US8153634B2 (en) | 2012-04-10 |
JP5541803B2 (ja) | 2014-07-09 |
EA018584B1 (ru) | 2013-09-30 |
EP2281817A4 (en) | 2011-10-05 |
EP2281817A1 (en) | 2011-02-09 |
ZA201008424B (en) | 2011-11-30 |
US20100048610A1 (en) | 2010-02-25 |
KR20110025899A (ko) | 2011-03-14 |
MX2010012882A (es) | 2010-12-14 |
TW201010983A (en) | 2010-03-16 |
AU2009252615B2 (en) | 2013-08-15 |
WO2009144961A1 (ja) | 2009-12-03 |
IL209489A0 (en) | 2011-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0913212A2 (pt) | composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
BRPI0821274A2 (pt) | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
BRPI0720637A2 (pt) | Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto | |
BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
BRPI0715888A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de mtor e um efeito anti-câncer em um animal de sangue quente e para tratar doenças em um animal de sangue quente. | |
BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
BRPI1009252A2 (pt) | composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BRPI0617241A2 (pt) | composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo | |
BRPI0917013A2 (pt) | métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BRPI0716092A2 (pt) | composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples. | |
BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
BR112015008365A2 (pt) | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
BRPI0809890A2 (pt) | Processo para preparar imatinib ou sal do mesmo e composição farmacêutica | |
BRPI0912348A2 (pt) | composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças | |
BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |